OPTIMIZE-1 primary analysis: Safety, efficacy and biomarker results of a phase 1b/2 study combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).

被引：0
|
作者：
Van Laethem, Jean-Luc
Borbath, Ivan
Geboes, Karen Paula
Cassier, Philippe Alexandre
Lambert, Aurelien
Mitry, Emmanuel
Prenen, Hans
Pilla, Lorenzo
Blanc, Jean-Frederic
Gallego Jimenez, Inmaculada
Cid, Roberto A. Pazo
Rodriguez Garrote, Mercedes
Feliu, Jaime
Nordbladh, Karin
Smith, Karin Enell
Gomez Jimenez, David
Ellmark, Peter
Pico de Coa, Yago
Ambarkhane, Sumeet Vijay
Macarulla, Teresa
机构：
[1] Erasme Univ Hosp, Brussels, Belgium
[2] St Luc Univ Clin, Brussels, Belgium
[3] Ghent Univ Hosp, Div Digest Oncol, Dept Gastroenterol, Ghent, Belgium
[4] Ctr Leon Berard, Lyon, France
[5] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France
[6] Inst Paoli Calmettes, Marseille, France
[7] Univ Hosp Gasthuisberg, Leuven, Belgium
[8] Univ Paris, Hop Europeen Georges Pompidou, AP HP, Dept Gastroenterol & Gastrointestinal Oncol, Paris, France
[9] Hop Haut Leveque, Pessac, France
[10] Hosp Univ Virgen Rocio, Seville, Spain
[11] Hosp Univ Miguel Servet, Zaragoza, Spain
[12] Hosp Univ Ramon y Cajal, Madrid, Spain
[13] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain
[14] Alligator Biosci AB, Lund, Sweden
[15] Vall Hebron Univ Hosp, Barcelona, Spain
[16] Vall Hebron Inst Oncol, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4133
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study
    Necchi, A.
    Todenhoefer, T.
    Deville, J-L
    Hackl, M.
    Marszewska, M.
    Mckernan, P.
    Saulay, M.
    Engelhardt, M.
    De Santis, M.
    EUROPEAN UROLOGY, 2023, 83 : S783 - S783
  • [42] Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPOLI-1 trial
    Chen, Li-Tzong
    Wang-Gillam, Andrea
    Yanshen, Shan
    Macarulla, Teresa
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Pipas, J. Marc
    Belanger, Bruce
    de Jong, Floris
    Mamlouk, Khalid
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [43] Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study.
    Necchi, Andrea
    Todenhoefer, Tilman
    Deville, Jean-Laurent
    Haeckl, Manuel
    Marszewska, Michalina
    McKernan, Phil
    Saulay, Mikael
    Engelhardt, Marc
    De Santis, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [44] Phase 1b Study of 2nd line vactosertib plus oxaliplatin with 5FU/LV (FOLFOX) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have failed firstline gemcitabine with nab-paclitaxel.
    Park, Joon Oh
    Kim, Seung Tae
    Hong, Eunji
    Hong, Jung Yong
    Park, Young Suk
    Kim, Seong-Jin
    CANCER RESEARCH, 2022, 82 (22) : 9 - 10
  • [45] Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
    Marcus Noel
    Eileen M. O’Reilly
    Brian M. Wolpin
    David P. Ryan
    Andrea J. Bullock
    Carolyn D. Britten
    David C. Linehan
    Brian A. Belt
    Eric C. Gamelin
    Bishu Ganguly
    Donghua Yin
    Tenshang Joh
    Ira A. Jacobs
    Carrie T. Taylor
    Maeve A. Lowery
    Investigational New Drugs, 2020, 38 : 800 - 811
  • [46] Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
    Noel, Marcus
    O'Reilly, Eileen M.
    Wolpin, Brian M.
    Ryan, David P.
    Bullock, Andrea J.
    Britten, Carolyn D.
    Linehan, David C.
    Belt, Brian A.
    Gamelin, Eric C.
    Ganguly, Bishu
    Yin, Donghua
    Joh, Tenshang
    Jacobs, Ira A.
    Taylor, Carrie T.
    Lowery, Maeve A.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 800 - 811
  • [47] Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Macarulla, Teresa Mercade
    Siveke, Jens T.
    Dean, Andrew Peter
    Hubner, Richard
    Blanc, Jean-Frederic
    Cunningham, David
    Chen, Li-Tzong
    Mirakhur, Beloo
    Chen, Jie
    de Jong, Floris A.
    Wang-Gillam, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [48] Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Siveke, Jens T.
    Hubner, Richard
    Macarulla, Teresa Mercade
    Wang-Gillam, Andrea
    Dean, Andrew Peter
    Blanc, Jean-Frederic
    Cunningham, David
    Mirakhur, Beloo
    Belanger, Bruce
    de Jong, Floris A.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [49] Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P plus Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC)
    Kapoun, A.
    O'Reilly, E.
    Cohn, A.
    Bendell, J. C.
    Smith, L.
    Strickler, J. H.
    Gluck, W.
    Liu, Y. W.
    Wallace, B.
    Tam, R.
    Cancilla, B.
    Brunner, A.
    Hill, D.
    Zhou, L.
    Dupont, J.
    Zhang, C.
    Wang, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 152 - 152
  • [50] Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
    Zeidan, Amer M.
    Schiller, Gary J.
    Lin, Tara L.
    Becker, Pamela S.
    Patel, Prapti A.
    Wang, Eunice S.
    Spira, Alexander I.
    Tsai, Michaela L.
    Ridinger, Maya
    Croucher, Peter J.
    Erlander, Mark
    Silberman, Sandra L.
    BLOOD, 2019, 134
12345